Smoking cessation is among the highest-impact interventions available in primary, respiratory, and cardiac care. The Nitof programme is designed to work alongside your clinical guidance - extending the reach of your prescription with a structured support ecosystem that continues well beyond the consultation room.
HHCL's Integrated Cessation Approach
Pharmacotherapeutic management of withdrawal symptoms through controlled nicotine delivery, stabilising neurological receptor activity.
Behavioural interventions targeting routine-based dependencies and hand-to-mouth synchronisation common in long-term use.
Counseling strategies to identify and mitigate environmental, emotional, and social stressors that provoke cravings.
Nitof's 21–14–7 mg architecture maps to patient dependency levels determined by Fagerström-based assessment. The systematic dose reduction is designed to allow gradual physiological adaptation to decreasing nicotine levels - significantly reducing withdrawal severity and relapse risk at each transition.
WEEKS 1-4
(heavy smokers)
WEEKS 5-8
(moderate/step-down)
WEEKS 9-12
(maintenance/light)
WEEKS 1-4
(heavy smokers)
WEEKS 5-8
(moderate/step-down)
WEEKS 9-12
(maintenance/light)
Nitof is indicated for adult smokers who are motivated to quit. Key clinical considerations:
© HeteroHealthcare Limited. All rights reserved. | heterohealthcare.com / nitof | For medical queries: consult your registered healthcare provider